ACS Medicinal Chemistry Letters (2020)
Update date:2022-09-26
Topics:
Aoyagi, Atsushi
Conrad, Jay
Droege, Daniel G.
Elepano, Manuel
Grandjean, Jean-Marc M.
Hirano, Shimpei
Hirasawa, Makoto
Hirouchi, Masakazu
Inoue, Masahiro
Jiu, Alexander Y.
Lee, Joanne
Murakami, Ryo
Ohyama, Takao
Olson, Steven H.
Paras, Nick A.
Prusiner, Stanley B.
Sasaki, Koji
Tang, Benjamin C.
Vaz, Roy J.
West, John W.
Tau prions feature in the brains of patients suffering from Alzheimer's disease and other tauopathies. For the development of therapeutics that target the replication of tau prions, a high-content, fluorescence-based cell assay was developed. Using this high-content phenotypic screen for nascent tau prion formation, a 4-piperazine isoquinoline compound (1) was identified as a hit with an EC50 value of 390 nM and 0.04 Kp,uu. Analogs were synthesized using a hypothesis-based approach to improve potency and in vivo brain penetration resulting in compound 25 (EC50 = 15 nM; Kp,uu = 0.63). We investigated the mechanism of action of this series and found that a small set of active compounds were also CDK8 inhibitors.
View MoreContact:
Address:No.89,Xinhua Road, Langfang City,Hebei China
Pengchen New Material Technology Co., Ltd.
Contact:+86-512-63680537
Address:99.6 km of national road 318, Meiyan Community,Pingwang Town, Wujiang District, Suzhou 215225
Jiangxi Dongxu Chemical Science & Technology Co.,Ltd
Contact:+86-791-86899381
Address:Nanchang, Jiangxi, China
Shanghai Rainbow Chemistry Co., Ltd.
Contact:+86-21-64968086-5815/5812
Address:3rd floor, Building 7, 251 Faladi Road, Zhangjiang Hi-Tech Park, Pudong District, Shanghai, P.R. China
Liao Cheng All Win Chemicals Co.,LTD
Contact:86+0635-2991582
Address:Room 402,Unit 1,No.27 building.Zhong tong shi dai haoyuan,liaocheng city,Shan dong Province.China
Doi:10.1021/bi00835a055
(1969)Doi:10.1021/jo9605814
(1996)Doi:10.1021/ja01207a038
(1946)Doi:10.1007/BF02494755
(1999)Doi:10.1021/jm9605593
(1997)Doi:10.1016/0968-0896(96)00094-6
(1996)